Search results
Results From The WOW.Com Content Network
Hemolytic–uremic syndrome (HUS) is a group of blood disorders characterized by low red blood cells, acute kidney injury (previously called acute renal failure), and low platelets. [1] [3] Initial symptoms typically include bloody diarrhea, fever, vomiting, and weakness. [1] [2] Kidney problems and low platelets then occur as the diarrhea ...
Atypical hemolytic uremic syndrome (aHUS), also known as complement-mediated hemolytic uremic syndrome (not to be confused with hemolytic–uremic syndrome), is an extremely rare, life-threatening, progressive disease that frequently has a genetic component. In most cases, it can be effectively controlled by interruption of the complement cascade.
Danicopan, sold under the brand name Voydeya, is a medication used for the treatment of paroxysmal nocturnal hemoglobinuria. It is a complement inhibitor which reversibly binds to factor D to prevent alternative pathway-mediated hemolysis and deposition of complement C3 proteins on red blood cells. The most common side effects include fever, headache, increased levels of liver enzymes (a sign ...
Hemoglobinuria is a condition in which the oxygen transport protein hemoglobin is found in abnormally high concentrations in the urine. [1] The condition is caused by excessive intravascular hemolysis, in which large numbers of red blood cells (RBCs) are destroyed, thereby releasing free hemoglobin into the plasma. [2]
Uremia is the condition of having high levels of urea in the blood. Urea is one of the primary components of urine.It can be defined as an excess in the blood of amino acid and protein metabolism end products, such as urea and creatinine, which would normally be excreted in the urine.
Hemolytic–uremic syndrome, a group of blood disorders characterized by low red blood cells, acute kidney injury, and low platelets House ( Hus ), a single-unit residential building Huastec language (ISO 639-3 code: hus), spoken by the Téenek people living in rural areas of San Luis Potosí and northern Veracruz
The European Medicines Agency approved it for the treatment of paroxysmal nocturnal hemoglobinuria in June 2007, [7] and in November 2011, for the treatment of atypical hemolytic uremic syndrome. [24] Health Canada approved it in 2009, to treat paroxysmal nocturnal hemoglobinuria and in 2013, as the only drug to treat atypical hemolytic uremic ...
Acute uric acid nephropathy is caused by deposition of uric acid crystals within the kidney interstitium and tubules, leading to partial or complete obstruction of collecting ducts, renal pelvis, or ureter. This obstruction is usually bilateral, and patients follow the clinical course of acute kidney failure.